Literature DB >> 20939738

Sequence variations in mitochondrial ferritin: distribution in healthy controls and different types of patients.

Emanuela Castiglioni1, Dario Finazzi, Stefano Goldwurm, Sonia Levi, Gianni Pezzoli, Barbara Garavaglia, Nardo Nardocci, Luca Malcovati, Matteo G Della Porta, Anna Gallì, Gian Luca Forni, Domenico Girelli, Federica Maccarinelli, Maura Poli, Maurizio Ferrari, Laura Cremonesi, Paolo Arosio.   

Abstract

The storage of iron in the cells is mainly accomplished by cytosolic ferritins. The perturbation of ferritin function may result in accumulation of excess iron in cells and tissues and increased oxidative stress, common features of different genetic and acquired disorders. Mutations in L-ferritin have been associated with neuroferritinopathy, a rare and severe movement disorder with abnormal brain iron storage. Recently, a novel form of ferritin has been discovered, which localizes in the mitochondrial matrix and plays an important role in iron homeostasis in these organelles. The possible association of sequence variations in the mitochondrial ferritin (FtMt) gene with disorders with aberrant iron distribution has not been investigated yet. We set up a denaturing high-performance liquid chromatography (DHPLC)-based screening for FtMt and analyzed the genomic DNA of patients with myelodysplastic syndromes (# 63) or with Parkinson's disease (# 332) and other movement disorders such as pantothenate kinase-associated neurodegeneration (# 7), restless legs syndrome (# 23), and suspected neuroferritinopathy (# 7) and of control subjects (# 342). We detected eight different types of substitution, all at the heterozygous state. Six of them caused amino acid changes, but none of them was predicted to drastically perturb FtMt structure and/or function. The c + 134C > A (P45H) variation, which was the most common (# 28), was less represented in the Parkinson's population, although not significantly (p = 0.07). The analysis suggests that sequence variations in the coding region of FtMt are not involved in the development of myelodysplastic syndromes and Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20939738     DOI: 10.1089/gtmb.2010.0076

Source DB:  PubMed          Journal:  Genet Test Mol Biomarkers        ISSN: 1945-0257


  4 in total

1.  Analysis of nucleotide variations in genes of iron management in patients of Parkinson's disease and other movement disorders.

Authors:  Emanuela Castiglioni; Dario Finazzi; Stefano Goldwurm; Gianni Pezzoli; Gianluca Forni; Domenico Girelli; Federica Maccarinelli; Maura Poli; Maurizio Ferrari; Laura Cremonesi; Paolo Arosio
Journal:  Parkinsons Dis       Date:  2010-10-17

Review 2.  Iron in Restless Legs Syndrome.

Authors:  Eva C Schulte; Maria Kaffe; Barbara Schormair; Juliane Winkelmann
Journal:  Mov Disord Clin Pract       Date:  2014-06-12

3.  Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study.

Authors:  Irene Pichler; Fabiola Del Greco M; Martin Gögele; Christina M Lill; Lars Bertram; Chuong B Do; Nicholas Eriksson; Tatiana Foroud; Richard H Myers; Michael Nalls; Margaux F Keller; Beben Benyamin; John B Whitfield; Peter P Pramstaller; Andrew A Hicks; John R Thompson; Cosetta Minelli
Journal:  PLoS Med       Date:  2013-06-04       Impact factor: 11.069

4.  Mice lacking mitochondrial ferritin are more sensitive to doxorubicin-mediated cardiotoxicity.

Authors:  Federica Maccarinelli; Elena Gammella; Michela Asperti; Maria Regoni; Giorgio Biasiotto; Emilia Turco; Fiorella Altruda; Silvia Lonardi; Laura Cornaghi; Elena Donetti; Stefania Recalcati; Maura Poli; Dario Finazzi; Paolo Arosio; Gaetano Cairo
Journal:  J Mol Med (Berl)       Date:  2014-04-13       Impact factor: 4.599

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.